There are 2949 resources available
914MO - Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial
Presenter: Christian Borel
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
915MO - Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Richard Greil
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
916MO - Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC)
Presenter: Charu Aggarwal
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
917MO - TOPNIVO - A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): Final analysis
Presenter: Caroline Even
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
918MO - Molecular enrichment and outcomes based on ESCAT levels in metastatic salivary gland tumours (mSGT) patients (pts) treated in early clinical trials
Presenter: Alberto Hernando-Calvo
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
919MO - ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
Presenter: Renata Ferrarotto
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
277MO - SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study
Presenter: Sarat Chandarlapaty
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
278MO - cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients
Presenter: Boris Krastev
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
279MO - Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008-2016
Presenter: Suzette Delaloge
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
280MO - Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study
Presenter: Pauline Corbaux
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast